JP4598404B2 - プロテインａ組成物および使用方法 - Google Patents
プロテインａ組成物および使用方法 Download PDFInfo
- Publication number
- JP4598404B2 JP4598404B2 JP2003583342A JP2003583342A JP4598404B2 JP 4598404 B2 JP4598404 B2 JP 4598404B2 JP 2003583342 A JP2003583342 A JP 2003583342A JP 2003583342 A JP2003583342 A JP 2003583342A JP 4598404 B2 JP4598404 B2 JP 4598404B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- effective amount
- monomeric protein
- protein
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims description 90
- 108090000623 proteins and genes Proteins 0.000 title claims description 62
- 102000004169 proteins and genes Human genes 0.000 title claims description 58
- 238000000034 method Methods 0.000 title description 107
- 238000011282 treatment Methods 0.000 claims description 82
- 210000004027 cell Anatomy 0.000 claims description 67
- 230000004054 inflammatory process Effects 0.000 claims description 62
- 206010061218 Inflammation Diseases 0.000 claims description 61
- 208000026278 immune system disease Diseases 0.000 claims description 56
- 230000000451 tissue damage Effects 0.000 claims description 50
- 210000004698 lymphocyte Anatomy 0.000 claims description 43
- 208000024891 symptom Diseases 0.000 claims description 37
- 230000005779 cell damage Effects 0.000 claims description 31
- 208000037887 cell injury Diseases 0.000 claims description 29
- 208000023275 Autoimmune disease Diseases 0.000 claims description 18
- 230000001603 reducing effect Effects 0.000 claims description 18
- 230000016784 immunoglobulin production Effects 0.000 claims description 17
- 230000001404 mediated effect Effects 0.000 claims description 17
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 17
- 230000005764 inhibitory process Effects 0.000 claims description 14
- 230000009467 reduction Effects 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 206010019233 Headaches Diseases 0.000 claims description 8
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 8
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 8
- 206010028813 Nausea Diseases 0.000 claims description 8
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 8
- 230000004663 cell proliferation Effects 0.000 claims description 8
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 8
- 231100000869 headache Toxicity 0.000 claims description 8
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 8
- 230000008693 nausea Effects 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 230000008961 swelling Effects 0.000 claims description 8
- 206010023230 Joint stiffness Diseases 0.000 claims description 7
- 208000002193 Pain Diseases 0.000 claims description 7
- 206010037660 Pyrexia Diseases 0.000 claims description 7
- 206010042674 Swelling Diseases 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 description 79
- 241001465754 Metazoa Species 0.000 description 63
- 210000001519 tissue Anatomy 0.000 description 59
- 230000028709 inflammatory response Effects 0.000 description 50
- 210000004988 splenocyte Anatomy 0.000 description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 45
- 230000007812 deficiency Effects 0.000 description 44
- 230000002159 abnormal effect Effects 0.000 description 41
- 241000699670 Mus sp. Species 0.000 description 36
- 230000004044 response Effects 0.000 description 34
- 230000004069 differentiation Effects 0.000 description 33
- 231100000827 tissue damage Toxicity 0.000 description 30
- 210000000952 spleen Anatomy 0.000 description 28
- 210000001744 T-lymphocyte Anatomy 0.000 description 27
- 230000028993 immune response Effects 0.000 description 27
- 208000011580 syndromic disease Diseases 0.000 description 27
- 230000006378 damage Effects 0.000 description 26
- 208000035475 disorder Diseases 0.000 description 24
- 230000035755 proliferation Effects 0.000 description 24
- 230000006907 apoptotic process Effects 0.000 description 22
- 210000000056 organ Anatomy 0.000 description 21
- 230000012010 growth Effects 0.000 description 20
- 201000010099 disease Diseases 0.000 description 19
- 239000003226 mitogen Substances 0.000 description 19
- 230000004727 humoral immunity Effects 0.000 description 18
- 230000008569 process Effects 0.000 description 18
- 210000004989 spleen cell Anatomy 0.000 description 18
- 208000029462 Immunodeficiency disease Diseases 0.000 description 17
- 206010061598 Immunodeficiency Diseases 0.000 description 16
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 16
- 230000007813 immunodeficiency Effects 0.000 description 16
- 231100000617 superantigen Toxicity 0.000 description 16
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 230000027455 binding Effects 0.000 description 14
- 230000007969 cellular immunity Effects 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- 230000001154 acute effect Effects 0.000 description 13
- 210000003719 b-lymphocyte Anatomy 0.000 description 13
- 230000003013 cytotoxicity Effects 0.000 description 13
- 231100000135 cytotoxicity Toxicity 0.000 description 13
- 231100000673 dose–response relationship Toxicity 0.000 description 13
- 206010058314 Dysplasia Diseases 0.000 description 12
- 208000009386 Experimental Arthritis Diseases 0.000 description 12
- 230000001684 chronic effect Effects 0.000 description 12
- 230000007423 decrease Effects 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 230000000638 stimulation Effects 0.000 description 12
- 206010041660 Splenomegaly Diseases 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 230000005856 abnormality Effects 0.000 description 9
- 210000003423 ankle Anatomy 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 210000003127 knee Anatomy 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 230000004584 weight gain Effects 0.000 description 9
- 235000019786 weight gain Nutrition 0.000 description 9
- 238000010171 animal model Methods 0.000 description 8
- 230000001363 autoimmune Effects 0.000 description 8
- 210000001541 thymus gland Anatomy 0.000 description 8
- 208000020053 Abnormal inflammatory response Diseases 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 230000007547 defect Effects 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000017423 tissue regeneration Effects 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 230000005784 autoimmunity Effects 0.000 description 6
- 230000024245 cell differentiation Effects 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000010534 mechanism of action Effects 0.000 description 6
- 210000000822 natural killer cell Anatomy 0.000 description 6
- 230000008816 organ damage Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 230000003405 preventing effect Effects 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 208000008190 Agammaglobulinemia Diseases 0.000 description 5
- 108010062580 Concanavalin A Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 108010047620 Phytohemagglutinins Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000011651 chromium Substances 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 210000003811 finger Anatomy 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 238000010606 normalization Methods 0.000 description 5
- 230000001885 phytohemagglutinin Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 210000001258 synovial membrane Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 4
- 102000055025 Adenosine deaminases Human genes 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- 201000010374 Down Syndrome Diseases 0.000 description 4
- 206010013883 Dwarfism Diseases 0.000 description 4
- 206010053759 Growth retardation Diseases 0.000 description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 4
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 4
- 208000007924 IgA Deficiency Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010039915 Selective IgA immunodeficiency Diseases 0.000 description 4
- 206010044688 Trisomy 21 Diseases 0.000 description 4
- 230000010398 acute inflammatory response Effects 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 230000007402 cytotoxic response Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 210000003981 ectoderm Anatomy 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 231100000001 growth retardation Toxicity 0.000 description 4
- 206010021198 ichthyosis Diseases 0.000 description 4
- 230000005965 immune activity Effects 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 201000007156 immunoglobulin alpha deficiency Diseases 0.000 description 4
- 108010085650 interferon gamma receptor Proteins 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000008747 mitogenic response Effects 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 239000005022 packaging material Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000000611 regression analysis Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 208000029138 selective IgA deficiency disease Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- 206010003591 Ataxia Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010010099 Combined immunodeficiency Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 102000004560 Interleukin-12 Receptors Human genes 0.000 description 3
- 108010017515 Interleukin-12 Receptors Proteins 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 210000000628 antibody-producing cell Anatomy 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 210000000544 articulatio talocruralis Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000005584 early death Effects 0.000 description 3
- 210000001513 elbow Anatomy 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 210000002832 shoulder Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000003371 toe Anatomy 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 210000000707 wrist Anatomy 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 2
- 206010053622 Asplenia Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
- 208000005692 Bloom Syndrome Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 201000007155 CD40 ligand deficiency Diseases 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 208000002691 Choroiditis Diseases 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 208000037051 Chromosomal Instability Diseases 0.000 description 2
- 208000031639 Chromosome Deletion Diseases 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 description 2
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 208000027219 Deficiency disease Diseases 0.000 description 2
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 201000004315 EAST syndrome Diseases 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 201000004939 Fanconi anemia Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 description 2
- 208000033311 Hereditary orotic aciduria Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 description 2
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010049645 Hypercatabolism Diseases 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000033321 ICF syndrome Diseases 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- 208000034174 Immunodeficiency by defective expression of MHC class II Diseases 0.000 description 2
- 206010022491 Insulin resistant diabetes Diseases 0.000 description 2
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 description 2
- 102100036157 Interferon gamma receptor 2 Human genes 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- 208000007672 Intestinal Lymphangiectasis Diseases 0.000 description 2
- 208000016051 Intestinal lymphangiectasia Diseases 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 2
- 201000009635 MHC class II deficiency Diseases 0.000 description 2
- 208000027933 Mannosidase Deficiency disease Diseases 0.000 description 2
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 description 2
- 208000011219 Netherton syndrome Diseases 0.000 description 2
- 208000007279 Papillon-Lefevre Disease Diseases 0.000 description 2
- 208000035884 Papillon-Lefèvre syndrome Diseases 0.000 description 2
- 201000011152 Pemphigus Diseases 0.000 description 2
- 241000721454 Pemphigus Species 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000009097 Phosphorylases Human genes 0.000 description 2
- 108010073135 Phosphorylases Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 206010065159 Polychondritis Diseases 0.000 description 2
- 208000003971 Posterior uveitis Diseases 0.000 description 2
- 206010063493 Premature ageing Diseases 0.000 description 2
- 208000032038 Premature aging Diseases 0.000 description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
- 206010036774 Proctitis Diseases 0.000 description 2
- 208000008425 Protein deficiency Diseases 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 102000001183 RAG-1 Human genes 0.000 description 2
- 108060006897 RAG1 Proteins 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- 102100027720 SH2 domain-containing protein 1A Human genes 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 206010057863 Selective IgG subclass deficiency Diseases 0.000 description 2
- 108010011033 Signaling Lymphocytic Activation Molecule Associated Protein Proteins 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 2
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 2
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 208000021914 Transcobalamin deficiency Diseases 0.000 description 2
- 208000026928 Turner syndrome Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- 206010047124 Vasculitis necrotising Diseases 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- 208000016349 X-linked agammaglobulinemia Diseases 0.000 description 2
- 208000029625 X-linked lymphoproliferative disease due to SH2D1A deficiency Diseases 0.000 description 2
- 206010068348 X-linked lymphoproliferative syndrome Diseases 0.000 description 2
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 description 2
- 201000004982 autoimmune uveitis Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000022159 cartilage development Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000012085 chronic inflammatory response Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- -1 coatings Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000012224 gene deletion Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 208000007345 glycogen storage disease Diseases 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 102000002467 interleukin receptors Human genes 0.000 description 2
- 108010093036 interleukin receptors Proteins 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 201000004614 iritis Diseases 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 description 2
- 201000011486 lichen planus Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 201000003694 methylmalonic acidemia Diseases 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 230000002956 necrotizing effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 201000009442 piebaldism Diseases 0.000 description 2
- 208000000992 pigmentary dilution Diseases 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 239000002213 purine nucleotide Substances 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 231100001055 skeletal defect Toxicity 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000003813 thumb Anatomy 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 206010049466 Erythroblastosis Diseases 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 208000035149 Immunodeficiency by defective expression of MHC class I Diseases 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 201000007114 MHC class I deficiency Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000002663 Surrogate Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010018324 Surrogate Immunoglobulin Light Chains Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 201000001322 T cell deficiency Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000012827 T-B+ severe combined immunodeficiency due to gamma chain deficiency Diseases 0.000 description 1
- 208000027912 T-cell immunodeficiency Diseases 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010070517 Type 2 lepra reaction Diseases 0.000 description 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 description 1
- 201000007146 X-linked severe combined immunodeficiency Diseases 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000037037 animal physiology Effects 0.000 description 1
- 238000004135 animal tissue culture Methods 0.000 description 1
- 230000003429 anti-cardiolipin effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000011111 cardboard Substances 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012888 cubic function Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000002554 disease preventive effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 206010016165 failure to thrive Diseases 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 230000008935 histological improvement Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 210000002861 immature t-cell Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000010262 intracellular communication Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000009701 normal cell proliferation Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000011087 paperboard Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920005575 poly(amic acid) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000012887 quadratic function Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009703 regulation of cell differentiation Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002325 super-antigenic effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Pregnancy & Childbirth (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/121,481 US7211258B2 (en) | 2002-04-10 | 2002-04-10 | Protein A compositions and methods of use |
| PCT/US2003/007019 WO2003086317A2 (en) | 2002-04-10 | 2003-03-06 | Protein a compositions and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009256593A Division JP5523796B2 (ja) | 2002-04-10 | 2009-11-09 | プロテインａ組成物および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005527581A JP2005527581A (ja) | 2005-09-15 |
| JP2005527581A5 JP2005527581A5 (enExample) | 2006-04-13 |
| JP4598404B2 true JP4598404B2 (ja) | 2010-12-15 |
Family
ID=29248302
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003583342A Expired - Fee Related JP4598404B2 (ja) | 2002-04-10 | 2003-03-06 | プロテインａ組成物および使用方法 |
| JP2009256593A Expired - Lifetime JP5523796B2 (ja) | 2002-04-10 | 2009-11-09 | プロテインａ組成物および使用方法 |
| JP2013227980A Withdrawn JP2014024865A (ja) | 2002-04-10 | 2013-11-01 | プロテインａ組成物および使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009256593A Expired - Lifetime JP5523796B2 (ja) | 2002-04-10 | 2009-11-09 | プロテインａ組成物および使用方法 |
| JP2013227980A Withdrawn JP2014024865A (ja) | 2002-04-10 | 2013-11-01 | プロテインａ組成物および使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US7211258B2 (enExample) |
| EP (2) | EP2570136B1 (enExample) |
| JP (3) | JP4598404B2 (enExample) |
| AU (1) | AU2003220085A1 (enExample) |
| CA (2) | CA2894098C (enExample) |
| ES (2) | ES2629687T3 (enExample) |
| WO (1) | WO2003086317A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7425331B2 (en) * | 2002-04-10 | 2008-09-16 | Protalex, Inc. | Protein A methods of use |
| US7211258B2 (en) * | 2002-04-10 | 2007-05-01 | Protalex, Inc. | Protein A compositions and methods of use |
| WO2004093907A2 (en) * | 2003-04-23 | 2004-11-04 | Tomoaki Hoshino | Therapeutic agents for treating dermatitis, alopecia and itching and transgenic animals for evaluating such therapeutic agents |
| US7691608B2 (en) * | 2006-12-06 | 2010-04-06 | Repligen Corporation | Nucleic acids encoding recombinant protein A |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2853453A1 (de) * | 1978-12-11 | 1980-06-19 | Behringwerke Ag | Mittel zur therapie von immunkomplexerkrankungen |
| US4315028A (en) * | 1978-12-22 | 1982-02-09 | Scheinberg Israel H | Method of treatment of rheumatoid arthritis |
| US5189014A (en) * | 1979-12-03 | 1993-02-23 | Cowan Jr Fred M | Method of treating cellular Fc receptor mediated hypersensitivity immune disorders |
| US4355029A (en) * | 1981-06-01 | 1982-10-19 | Eli Lilly And Company | Combination therapy for rheumatoid arthritis |
| US5091091A (en) | 1981-11-06 | 1992-02-25 | Terman David S | Protein A perfusion and post perfusion drug infusion |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4402965A (en) * | 1982-08-05 | 1983-09-06 | John R. A. Simoons | Treatment of rheumatoid arthritis and related diseases |
| US4699783A (en) * | 1983-03-11 | 1987-10-13 | Terman David S | Products and methods for treatment of cancer |
| US4617266A (en) | 1983-04-28 | 1986-10-14 | Genex Corporation | Production of Protein A |
| FR2556219B1 (fr) * | 1983-12-07 | 1987-06-26 | Merieux Inst | Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines |
| US4681870A (en) * | 1985-01-11 | 1987-07-21 | Imre Corporation | Protein A-silica immunoadsorbent and process for its production |
| US4628052A (en) * | 1985-05-28 | 1986-12-09 | Peat Raymond F | Pharmaceutical compositions containing dehydroepiandrosterone and other anesthetic steroids in the treatment of arthritis and other joint disabilities |
| DK528285D0 (da) * | 1985-11-15 | 1985-11-15 | Novo Industri As | Peptider samt praeparater indeholdende disse |
| US5985599A (en) * | 1986-05-29 | 1999-11-16 | The Austin Research Institute | FC receptor for immunoglobulin |
| US5362490A (en) * | 1986-07-25 | 1994-11-08 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Human myelomonocyte interferon-gamma, and process for preparation and use thereof |
| US5782792A (en) * | 1986-11-21 | 1998-07-21 | Cypress Bioscience, Inc. | Method for treatment of rheumatoid arthritis |
| US4863869A (en) * | 1986-11-21 | 1989-09-05 | Imre Cororation | Anti-human IGM immunoadsorbent and process for producing said immunoadsorbent |
| US5122112A (en) * | 1986-11-21 | 1992-06-16 | Imre Corporation | Antigen-specific removal of circulating immune complexes |
| US5084559A (en) * | 1987-03-27 | 1992-01-28 | Repligen Corporation | Protein a domain mutants |
| US4925920A (en) * | 1987-05-29 | 1990-05-15 | Brigham And Women's Hospital | Immunosuppressive polypeptides |
| US5084398A (en) * | 1987-11-20 | 1992-01-28 | Creative Biomolecules | Selective removal of immune complexes |
| JPH0211523A (ja) * | 1988-06-30 | 1990-01-16 | Sekisui Chem Co Ltd | 悪性腫瘍等の治療用免疫吸着剤およびそれを用いた治療方法 |
| US5240601A (en) * | 1988-11-09 | 1993-08-31 | Chembiomed, Ltd. | Affinity supports for hemoperfusion |
| US5077284A (en) * | 1988-12-30 | 1991-12-31 | Loria Roger M | Use of dehydroepiandrosterone to improve immune response |
| US6042837A (en) * | 1989-09-20 | 2000-03-28 | Kalland; Terje | Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC) |
| US5728388A (en) * | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| US6126945A (en) * | 1989-10-03 | 2000-10-03 | Pharmacia Ab | Tumor killing effects of enterotoxins, superantigens, and related compounds |
| GB9013872D0 (en) | 1990-06-21 | 1990-08-15 | Inst Tecnologico Y Cientifico | Use of protein a and polypeptide components thereof in the treatment of tumours |
| US5230887A (en) * | 1990-07-11 | 1993-07-27 | Immune Network Research Ltd. | Immune system stabilizers for prevention and therapy of disorders associated with immune system disfunction |
| GB9022648D0 (en) * | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
| US5476929A (en) | 1991-02-15 | 1995-12-19 | Uab Research Foundation | Structural gene of pneumococcal protein |
| WO1992019240A1 (en) * | 1991-05-01 | 1992-11-12 | University Of New Mexico | Treatment of aberrant cellular states with biomodulators |
| US5422427A (en) | 1991-09-17 | 1995-06-06 | The United States Of America As Represented By The United States Department Of Health And Human Services | Pneumococcal fimbrial protein A |
| US6312944B1 (en) | 1991-11-14 | 2001-11-06 | The United States Of America As Represented By The Department Of Health And Human Services | Pneumococcal fimbrial protein A |
| US5277701A (en) * | 1991-11-15 | 1994-01-11 | Regents Of The University Of Minnesota | Treatment of aluimmunization and refractoriness to platelet transfusion by protein A column therapy |
| US5304529A (en) * | 1992-03-30 | 1994-04-19 | Tropicana Products, Inc. | Synergistic mixture of bioregulator compounds and method of their use |
| JP3714683B2 (ja) * | 1992-07-30 | 2005-11-09 | 生化学工業株式会社 | 抗リウマチ剤 |
| CA2105629A1 (en) * | 1992-09-14 | 1994-03-15 | Robert S. Becker | Potentiation of immunogenic response |
| AU5152293A (en) * | 1992-10-08 | 1994-05-09 | Kennedy Institute Of Rheumatology, The | Treatment of autoimmune and inflammatory disorders |
| US5753227A (en) * | 1993-07-23 | 1998-05-19 | Strahilevitz; Meir | Extracorporeal affinity adsorption methods for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases |
| US5858981A (en) * | 1993-09-30 | 1999-01-12 | University Of Pennsylvania | Method of inhibiting phagocytosis |
| GB9320820D0 (en) * | 1993-10-08 | 1993-12-01 | Biokine Tech Ltd | Compounds for medicinal use |
| CA2176948C (en) * | 1993-11-30 | 2007-05-15 | Halle Morton | Chaperonin 10 |
| JP3574471B2 (ja) * | 1994-05-18 | 2004-10-06 | 株式会社クラレ | 抗表皮細胞間抗体結合性ペプチドおよび吸着剤 |
| CN1136016C (zh) * | 1995-07-10 | 2004-01-28 | 旭医学株式会社 | 用于治疗炎性疾病的体外循环血液处理系统 |
| US6447777B1 (en) * | 1996-03-29 | 2002-09-10 | David S. Terman | Polymerized staphylococcal protein a for treatment of diseases |
| US6013763A (en) * | 1996-06-04 | 2000-01-11 | Genentech, Inc. | Peptide variants of protein A |
| US6245340B1 (en) * | 1996-12-03 | 2001-06-12 | Parvin Youssefyeh | Method of improving the immune response and compositions therefor |
| US6555661B1 (en) * | 1997-08-25 | 2003-04-29 | Anthony R. Torres | Simple, environmentally benign, method for purifying protein A |
| WO2000069457A1 (en) | 1999-05-15 | 2000-11-23 | University Of California, San Diego | Protein a based binding domains with desirable activities |
| US7163686B1 (en) * | 1999-05-15 | 2007-01-16 | The Regents Of The University Of California | Protein A based binding domains with desirable activities |
| US7211258B2 (en) | 2002-04-10 | 2007-05-01 | Protalex, Inc. | Protein A compositions and methods of use |
| US7425331B2 (en) | 2002-04-10 | 2008-09-16 | Protalex, Inc. | Protein A methods of use |
-
2002
- 2002-04-10 US US10/121,481 patent/US7211258B2/en not_active Expired - Lifetime
-
2003
- 2003-03-06 ES ES03716375.5T patent/ES2629687T3/es not_active Expired - Lifetime
- 2003-03-06 CA CA2894098A patent/CA2894098C/en not_active Expired - Fee Related
- 2003-03-06 JP JP2003583342A patent/JP4598404B2/ja not_active Expired - Fee Related
- 2003-03-06 EP EP12177657.9A patent/EP2570136B1/en not_active Expired - Lifetime
- 2003-03-06 AU AU2003220085A patent/AU2003220085A1/en not_active Abandoned
- 2003-03-06 ES ES12177657.9T patent/ES2586120T3/es not_active Expired - Lifetime
- 2003-03-06 EP EP03716375.5A patent/EP1499345B1/en not_active Expired - Lifetime
- 2003-03-06 CA CA2481282A patent/CA2481282C/en not_active Expired - Fee Related
- 2003-03-06 WO PCT/US2003/007019 patent/WO2003086317A2/en not_active Ceased
-
2006
- 2006-11-14 US US11/559,713 patent/US7807170B2/en not_active Expired - Fee Related
-
2009
- 2009-11-09 JP JP2009256593A patent/JP5523796B2/ja not_active Expired - Lifetime
-
2010
- 2010-09-14 US US12/882,057 patent/US8168189B2/en not_active Expired - Fee Related
-
2012
- 2012-04-23 US US13/453,788 patent/US8603486B2/en not_active Expired - Fee Related
-
2013
- 2013-11-01 JP JP2013227980A patent/JP2014024865A/ja not_active Withdrawn
- 2013-12-05 US US14/098,146 patent/US9370552B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003086317A3 (en) | 2004-07-29 |
| ES2629687T3 (es) | 2017-08-14 |
| JP2014024865A (ja) | 2014-02-06 |
| JP2010031050A (ja) | 2010-02-12 |
| JP2005527581A (ja) | 2005-09-15 |
| US9370552B2 (en) | 2016-06-21 |
| US20070129285A1 (en) | 2007-06-07 |
| US7211258B2 (en) | 2007-05-01 |
| EP1499345B1 (en) | 2017-04-26 |
| EP2570136A3 (en) | 2013-06-12 |
| CA2894098A1 (en) | 2003-10-23 |
| US7807170B2 (en) | 2010-10-05 |
| WO2003086317A2 (en) | 2003-10-23 |
| ES2586120T3 (es) | 2016-10-11 |
| US20140093539A1 (en) | 2014-04-03 |
| EP2570136B1 (en) | 2016-05-04 |
| CA2894098C (en) | 2016-12-06 |
| JP5523796B2 (ja) | 2014-06-18 |
| US20120294895A1 (en) | 2012-11-22 |
| US8168189B2 (en) | 2012-05-01 |
| EP1499345A2 (en) | 2005-01-26 |
| US8603486B2 (en) | 2013-12-10 |
| AU2003220085A1 (en) | 2003-10-27 |
| AU2003220085A8 (en) | 2003-10-27 |
| CA2481282C (en) | 2016-12-13 |
| EP1499345A4 (en) | 2009-08-05 |
| US20030211986A1 (en) | 2003-11-13 |
| CA2481282A1 (en) | 2003-10-23 |
| US20110064762A1 (en) | 2011-03-17 |
| EP2570136A2 (en) | 2013-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5523796B2 (ja) | プロテインａ組成物および使用方法 | |
| US20090239926A1 (en) | Methods for the treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-carboxamide | |
| US20220387317A1 (en) | Methods and compositions relating to selective intracellular delivery of cd38 inhibitors | |
| JP2015038152A (ja) | プロテインａ組成物およびその使用方法 | |
| Hendeles et al. | Evaluation of cytokine modulators for asthma | |
| Calabrese et al. | Thalidomide revisited: pharmacology and clinical applications | |
| US20090209581A1 (en) | Nitroxides for use in treating or preventing immunological diseases | |
| EP1501505B1 (en) | Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1h- 1,2,4 -triazole for the treatment of autoimmune diseases | |
| US20240239913A1 (en) | Compositions and methods for treating osteoarthritis using a cd14 inhibitor | |
| HK1145805A (en) | Protein a compositions and methods of use | |
| HK1145805B (en) | Protein a compositions and methods of use | |
| JP2022085645A (ja) | Ｃｘ３ｃｌ１を含有する認知機能改善剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060223 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060223 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090518 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090811 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090818 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091109 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20091109 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100416 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100416 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100705 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100805 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100810 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100901 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100924 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131001 Year of fee payment: 3 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131001 Year of fee payment: 3 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| LAPS | Cancellation because of no payment of annual fees |